Initial development of an evidence base for personalized medicine’s translation to clinical practice and health policy

Author:

Phillips Kathryn A1,Van Bebber Stephanie L1,Issa Amalia M2

Affiliation:

1. University of California, Department of Clinical Pharmacy, School of Pharmacy, San Francisco, 3333 California St Suite 420 Box 0613, University of California, San Francisco, CA 94143–0613, USA.

2. The Methodist Hospital and University of Houston, Program in Personalized Medicine & Targeted Therapeutics and the Abramson Center for the Future of Health, 300 Technology Building, T2–309, Houston, TX 77204–4021, USA.

Abstract

A major challenge to adoption of personalized medicine approaches, such as pharmacogenomics, is that data to address many critical questions relevant to clinical application, economics, policy and regulation are typically unavailable or widely dispersed. The evidence base we tentatively call Evaluation Data for Assessing Personalized Medicine Translation (EDAPT) would generate the foundation for a database of information. This article begins with a description of the rationale and conceptual framework for this effort.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3